Advent International and Avista Capital Partners have signed an agreement to acquire Kremers Urban Pharmaceuticals Inc., the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB, S.A., for $1.525 billion. The transaction is expected to close by the first quarter of 2015. Over the past seven years, Kremers has diversified and grown its product portfolio from one major product to more than 20 marketed products across a number of indications, including gastroe...